- Conditions
- Preeclampsia, Gestational Hypertension
- Interventions
- spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bioequivalence Study in Healthy Subjects, PK/PD
- Interventions
- 10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- End Stage Renal Disease, Hemodialysis
- Interventions
- Spironolactone, L-arginine, Placebo
- Drug · Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
- Interventions
- Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo
- Drug · Device
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Hypertension (HTN)
- Interventions
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Type 2 Diabetic Nephropathy
- Interventions
- PF-03882845, Spironolactone, placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 6
- States / cities
- Chula Vista, California • San Diego, California • DeLand, Florida + 3 more
- Conditions
- Bioavailability Heathy Volunteers
- Interventions
- Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Hyperkalemia, Resistant Hypertension
- Interventions
- Patiromer, Placebo, Spironolactone
- Drug
- Lead sponsor
- Relypsa, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Miami Lakes, Florida • Chicago, Illinois
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Spironolactone, Standard care
- Drug · Other
- Lead sponsor
- Uppsala University
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 38
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
- Conditions
- Healthy Participants
- Interventions
- Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas